16 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B Sell
Article Searches
Novo Nordisk Is on the Upswing -- for Now https://www.fool.com/investing/2019/02/05/novo-nordisk-is-on-the-upswing-for-now.aspx?source=iedfolrf0000001 Feb 05, 2019 - The full year may be a different story.
Sanofi's Myeloma Candidate Meets Goal in Phase III Study http://www.zacks.com/stock/news/352133/sanofis-myeloma-candidate-meets-goal-in-phase-iii-study?cid=CS-ZC-FT-352133 Feb 05, 2019 - Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Gilead to Collaborate with Novo Nordisk for NASH Treatment http://www.zacks.com/stock/news/381020/gilead-to-collaborate-with-novo-nordisk-for-nash-treatment?cid=CS-ZC-FT-381020 Apr 15, 2019 - Gilead Sciences (GILD) will collaborate with Novo Nordisk to develop treatments for liver disease, NASH.
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal http://www.zacks.com/stock/news/382518/biotech-stock-roundup-gild-collaborates-on-nash-fcsc-surges-on-deal?cid=CS-ZC-FT-382518 Apr 17, 2019 - Key highlights of the past week are collaborations and pipeline updates.
Novo Nordisk (NVO) Q4 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2019/02/02/novo-nordisk-nvo-q4-2018-earnings-conference-call.aspx?source=iedfolrf0000001 Feb 02, 2019 - NVO earnings call for the period ending December 31, 2018.
Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/351653/novo-nordisk-nvo-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-351653 Feb 01, 2019 - Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.
Novo Nordisk's (NVO) CEO Lars Fruergaard Jørgensen on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4237599-novo-nordisks-nvo-ceo-lars-fruergaard-jorgensen-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 01, 2019 - Novo Nordisk A/S (NYSE:NVO) Q4 2018 Earnings Conference Call February 1, 2019 7:00 AM ET Company Participants Lars Fruergaard Jørgensen – Chief Executive Officer Karsten Munk Knudsen – Chief Financial
Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer http://www.zacks.com/stock/news/352085/mercks-keytruda-clinches-chmp-nod-for-difficult-lung-cancer?cid=CS-ZC-FT-352085 Feb 05, 2019 - Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth http://www.zacks.com/stock/news/352788/sanofi-sny-q4-earnings-top-genzyme-unit-drives-sales-growth?cid=CS-ZC-FT-352788 Feb 07, 2019 - Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.
Seattle Genetics' Adcetris Gets EC Nod for Label Expansion http://www.zacks.com/stock/news/354019/seattle-genetics-adcetris-gets-ec-nod-for-label-expansion?cid=CS-ZC-FT-354019 Feb 12, 2019 - Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.

Pages: 12

Page 1